Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 11/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12896385 | 1.00 | TEAD1 (0.44) | TEAD1TAAR1HTR2CHTR2AHTR2B | |
| SCHEMBL12896383 | 1.00 | TEAD1 (0.44) | TEAD1TAAR1HTR2CHTR2AHTR2B | |
| SCHEMBL12305016 | 0.86 | TAAR1 (0.44) | TAAR1HTR2CHTR2AHTR2BMAOA | |
| SCHEMBL2740638 | 0.86 | TAAR1 (0.44) | TAAR1HTR2CHTR2AHTR2BMAOA | |
| SCHEMBL12923754 | 0.80 | CYP19A1 (0.42) | TEAD1HTR2CHTR2AHTR2B | |
| SCHEMBL12923876 | 0.80 | CYP19A1 (0.42) | TEAD1HTR2CHTR2AHTR2B | |
| SCHEMBL12923877 | 0.80 | CYP19A1 (0.42) | TEAD1HTR2CHTR2AHTR2B | |
| SCHEMBL12595267 | 0.79 | TAAR1 (0.49) | TAAR1HTR2CHTR2AHTR2BMAOA | |
| SCHEMBL12896371 | 0.79 | TP53 (0.42) | TEAD1TAAR1HTR2CHTR2AHTR2B | |
| SCHEMBL12896288 | 0.79 | TP53 (0.42) | TEAD1TAAR1HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149465-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, HRH2 | TEAD1 2965/4885TAAR1 620/4885HTR2C 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.